COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,397 Articles (22,816 medRxiv, 8,581 bioRxiv)

Most recent first Previous |  Page 1680: Articles 16791-16800  | Next

Monozygotic twins discordant for severe clinical recurrence of COVID-19 show drastically distinct T cell responses to SARS-Cov-2
Castro, M. V., Santos, K. S., Apostolico, J. S., Fernandes, E. R., Almeida, R. R., Levin, G., Magawa, J. Y., Nunes, J. P. S., Bruni, M., Yamamoto, M. M., Lima, A. C., Silva, M. V. R., Matos, L. R. B., Coria, V. R., Castelli, E. C., Scliar, M. O., Kuramoto, A., Bruno, F. R., Jacintho, L. C., Nunes, K., Wang, J. Y. T., Coelho, V. P., Mitne Neto, M., Maciel, R. M. B., Naslavsky, M. S., Passos-Bueno, M. R., Boscardin, S. B., Rosa, D. S., Kalil, J., Zatz, M., Cunha-Neto, E.
10.1101/2021.03.26.21253645 — Posted: 2021-03-28 Discussion: Onsite
Visible and real sizes of the COVID-19 pandemic in Ukraine
Nesteruk, I.
10.1101/2021.03.19.21253938 — Posted: 2021-03-27
International attitudes on COVID-19 vaccination: repeat national cross-sectional surveys across 15 countries
Fernandez Crespo, R., Shafat, M., Melas-Kyriazi, N., Gould, L. J., Jones, S., Neves, A. L., Leis, M. S., Maheswaran, H., Darzi, A.
10.1101/2021.03.08.21252449 — Posted: 2021-03-27
High Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Non-Covalent Inhibitor
Clyde, A., Galanie, S., Kneller, D. W., Ma, H., Babuji, Y., Blaiszik, B., Brace, A., Brettin, T., Chard, K., Chard, R., Coates, L., Foster, I., Hauner, D., Kertesz, V., Kumar, N., Lee, H., Li, Z., Merzky, A., Schmidt, J. G., Tan, L., Titov, M., Trifan, A., Turilli, M., Van Dam, H., Chennubhotla, S. C., Jha, S., Kovalevsky, A., Ramanathan, A., Head, M., Stevens, R.
10.1101/2021.03.27.437323 — Posted: 2021-03-27
The nucleotide addition cycle of the SARS-CoV-2 polymerase
Bera, S. C., Seifert, M., Kirchdoerfer, R., van Nies, P., Wubulikasimu, Y., Quack, S., Papini, F. S., Arnold, J. J., Canard, B., Cameron, C. E., Depken, M., Dulin, D.
10.1101/2021.03.27.437309 — Posted: 2021-03-27
Rapid Evolution of SARS-CoV-2 Challenges Human Defenses
Duarte, C. M., Ketcheson, D., Eguiluz, V. M., Agusti, S. R., Gracia, J. F., Jamil, T., Laiolo, E., Gojobori, T., Alam, I.
10.1101/2021.03.27.437300 — Posted: 2021-03-27 Discussion: Onsite
The RNA sensor MDA5 detects SARS-CoV-2 infection
Sampaio, N. G., Chauveau, L., Hertzog, J., Bridgeman, A., Fowler, G., Moonen, J. P., Dupont, M., Russel, R. A., Noerenberg, M., Rehwinkel, J.
10.1101/2021.03.26.437180 — Posted: 2021-03-27
Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants
Zhang, Y.-N., Paynter, J., Fourfouris, T., Sou, C., Ngo, T., He, L., Zhu, J.
10.1101/2021.03.26.437274 — Posted: 2021-03-27
Differential effect of corticosteroid treatment on Influenza, SARS, MERS, and SARS-CoV-2 patients: A meta-analysis and systematic review
Ali, S., Uddin, S. Z., Dewan, M. N., Moniruzzaman, M., Kabir, M. H., Islam, M. R., Monir, H., Hossan, S., Nafiz, T. N., Rashid, R., Imran, K. M.
10.1101/2021.03.22.21254104 — Posted: 2021-03-26 Discussion: Onsite
Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following Tocilizumab therapy: A systematic review to inform risk assessment in the COVID era
Campbell, C., Andersson, M., Ansari, M. A., Moswela, O., Misbah, S. A., Klenerman, P., Matthews, P. C.
10.1101/2021.03.22.21254128 — Posted: 2021-03-26

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).